Cargando…

Crosstalk between KIF1C and PRKAR1A in left atrial myxoma

Cardiac myxoma (CM) is the most common benign cardiac tumor, and most CMs are left atrial myxomas (LAMs). Six variations of KIF1C, c.899 A > T, c.772 T > G, c.352 A > T, c.2895 C > T, c.3049 G > A, and c.*442_*443dup in left atrial myxoma tissues are identified by whole-exome sequenci...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Mengchen, Yao, Yan, Wang, Xiangyi, Zha, Lingfeng, Chen, Yilin, Li, Yanze, Wang, Mengru, Yu, Chenguang, Zhou, Yingchao, Li, Qianqian, Cao, Zhubing, Wu, Jianfei, Shi, Shumei, Jiang, Dan, Long, Deyong, Wang, Jiangang, Wang, Qing, Cheng, Xiang, Liao, Yuhua, Tu, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349109/
https://www.ncbi.nlm.nih.gov/pubmed/37452081
http://dx.doi.org/10.1038/s42003-023-05094-5
_version_ 1785073828061249536
author Zhou, Mengchen
Yao, Yan
Wang, Xiangyi
Zha, Lingfeng
Chen, Yilin
Li, Yanze
Wang, Mengru
Yu, Chenguang
Zhou, Yingchao
Li, Qianqian
Cao, Zhubing
Wu, Jianfei
Shi, Shumei
Jiang, Dan
Long, Deyong
Wang, Jiangang
Wang, Qing
Cheng, Xiang
Liao, Yuhua
Tu, Xin
author_facet Zhou, Mengchen
Yao, Yan
Wang, Xiangyi
Zha, Lingfeng
Chen, Yilin
Li, Yanze
Wang, Mengru
Yu, Chenguang
Zhou, Yingchao
Li, Qianqian
Cao, Zhubing
Wu, Jianfei
Shi, Shumei
Jiang, Dan
Long, Deyong
Wang, Jiangang
Wang, Qing
Cheng, Xiang
Liao, Yuhua
Tu, Xin
author_sort Zhou, Mengchen
collection PubMed
description Cardiac myxoma (CM) is the most common benign cardiac tumor, and most CMs are left atrial myxomas (LAMs). Six variations of KIF1C, c.899 A > T, c.772 T > G, c.352 A > T, c.2895 C > T, c.3049 G > A, and c.*442_*443dup in left atrial myxoma tissues are identified by whole-exome sequencing (WES) and Sanger sequencing. RNA-seq and function experiments show the reduction of the expression of KIF1C and PRKAR1A caused by rare variations of KIF1C. KIF1C is observed to be located in the nucleus, bind to the promoter region of PRKAR1A, and regulate its transcription. Reduction of KIF1C decreases PRKAR1A expression and activates the PKA, which causes an increase in ERK1/2 phosphorylation and SRC-mediated STAT3 activation, a reduction of CDH1, TP53, CDKN1A, and BAX, and eventually promotes tumor formation both in vitro and in vivo. The results suggest that inhibition of KIF1C promotes the pathogenesis of LAM through positive feedback formed by the crosstalk between KIF1C and PRKAR1A.
format Online
Article
Text
id pubmed-10349109
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-103491092023-07-16 Crosstalk between KIF1C and PRKAR1A in left atrial myxoma Zhou, Mengchen Yao, Yan Wang, Xiangyi Zha, Lingfeng Chen, Yilin Li, Yanze Wang, Mengru Yu, Chenguang Zhou, Yingchao Li, Qianqian Cao, Zhubing Wu, Jianfei Shi, Shumei Jiang, Dan Long, Deyong Wang, Jiangang Wang, Qing Cheng, Xiang Liao, Yuhua Tu, Xin Commun Biol Article Cardiac myxoma (CM) is the most common benign cardiac tumor, and most CMs are left atrial myxomas (LAMs). Six variations of KIF1C, c.899 A > T, c.772 T > G, c.352 A > T, c.2895 C > T, c.3049 G > A, and c.*442_*443dup in left atrial myxoma tissues are identified by whole-exome sequencing (WES) and Sanger sequencing. RNA-seq and function experiments show the reduction of the expression of KIF1C and PRKAR1A caused by rare variations of KIF1C. KIF1C is observed to be located in the nucleus, bind to the promoter region of PRKAR1A, and regulate its transcription. Reduction of KIF1C decreases PRKAR1A expression and activates the PKA, which causes an increase in ERK1/2 phosphorylation and SRC-mediated STAT3 activation, a reduction of CDH1, TP53, CDKN1A, and BAX, and eventually promotes tumor formation both in vitro and in vivo. The results suggest that inhibition of KIF1C promotes the pathogenesis of LAM through positive feedback formed by the crosstalk between KIF1C and PRKAR1A. Nature Publishing Group UK 2023-07-14 /pmc/articles/PMC10349109/ /pubmed/37452081 http://dx.doi.org/10.1038/s42003-023-05094-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhou, Mengchen
Yao, Yan
Wang, Xiangyi
Zha, Lingfeng
Chen, Yilin
Li, Yanze
Wang, Mengru
Yu, Chenguang
Zhou, Yingchao
Li, Qianqian
Cao, Zhubing
Wu, Jianfei
Shi, Shumei
Jiang, Dan
Long, Deyong
Wang, Jiangang
Wang, Qing
Cheng, Xiang
Liao, Yuhua
Tu, Xin
Crosstalk between KIF1C and PRKAR1A in left atrial myxoma
title Crosstalk between KIF1C and PRKAR1A in left atrial myxoma
title_full Crosstalk between KIF1C and PRKAR1A in left atrial myxoma
title_fullStr Crosstalk between KIF1C and PRKAR1A in left atrial myxoma
title_full_unstemmed Crosstalk between KIF1C and PRKAR1A in left atrial myxoma
title_short Crosstalk between KIF1C and PRKAR1A in left atrial myxoma
title_sort crosstalk between kif1c and prkar1a in left atrial myxoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349109/
https://www.ncbi.nlm.nih.gov/pubmed/37452081
http://dx.doi.org/10.1038/s42003-023-05094-5
work_keys_str_mv AT zhoumengchen crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT yaoyan crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT wangxiangyi crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT zhalingfeng crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT chenyilin crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT liyanze crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT wangmengru crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT yuchenguang crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT zhouyingchao crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT liqianqian crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT caozhubing crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT wujianfei crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT shishumei crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT jiangdan crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT longdeyong crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT wangjiangang crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT wangqing crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT chengxiang crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT liaoyuhua crosstalkbetweenkif1candprkar1ainleftatrialmyxoma
AT tuxin crosstalkbetweenkif1candprkar1ainleftatrialmyxoma